Oprelvekin

Drug Profile

Oprelvekin

Alternative Names: Interleukin-11; Neumega; Recombinant human-interleukin-11; rhIL-11; SCH-53620; YM-294

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Class Antineoplastics; Chemoprotectants; Interleukins; Recombinant proteins
  • Mechanism of Action Interleukin 11 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Thrombocytopenia
  • Discontinued Bacteraemia; Crohn's disease; Graft-versus-host disease; Inflammatory bowel diseases; Mucositis; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 12 Aug 2016 Biomarkers information updated
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top